9X1 Stock Overview
Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Procaps Group S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.38 |
| 52 Week High | US$4.08 |
| 52 Week Low | US$1.88 |
| Beta | 0.13 |
| 1 Month Change | 4.39% |
| 3 Month Change | -20.13% |
| 1 Year Change | -39.59% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -74.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9X1 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 8.2% | 0.9% | -1.0% |
| 1Y | -39.6% | -27.7% | 2.0% |
Return vs Industry: 9X1 underperformed the German Pharmaceuticals industry which returned -27.7% over the past year.
Return vs Market: 9X1 underperformed the German Market which returned 2% over the past year.
Price Volatility
| 9X1 volatility | |
|---|---|
| 9X1 Average Weekly Movement | 11.8% |
| Pharmaceuticals Industry Average Movement | 7.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 9X1's share price has been volatile over the past 3 months.
Volatility Over Time: 9X1's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1977 | 5,500 | Jose Antonio Vieira | www.procapsgroup.com |
Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products.
Procaps Group S.A. Fundamentals Summary
| 9X1 fundamental statistics | |
|---|---|
| Market cap | €295.54m |
| Earnings (TTM) | €48.49m |
| Revenue (TTM) | €384.65m |
6.1x
P/E Ratio0.8x
P/S RatioIs 9X1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9X1 income statement (TTM) | |
|---|---|
| Revenue | US$414.10m |
| Cost of Revenue | US$186.19m |
| Gross Profit | US$227.91m |
| Other Expenses | US$175.71m |
| Earnings | US$52.20m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.46 |
| Gross Margin | 55.04% |
| Net Profit Margin | 12.61% |
| Debt/Equity Ratio | 663.2% |
How did 9X1 perform over the long term?
See historical performance and comparison